Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NB128
- Development stage
- Preclinical
- Lead developer
- Virpax Pharmaceuticals
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intranasal
01
Overview
NB128 (also known as NobrXiol) is an intranasal nanoparticle powder formulation of valproic acid developed using Nanomerics' proprietary Molecular Envelope Technology (MET). It is specifically designed for the treatment of treatment-resistant epilepsy. The MET platform utilizes amphiphilic polymers, such as chitosan-based GCPQ, to encapsulate small molecules into nanoparticles, facilitating direct nose-to-brain delivery via the olfactory and trigeminal nerve pathways. This approach aims to bypass the blood-brain barrier, increase cerebral bioavailability, and reduce systemic side effects typically associated with oral valproate therapy. The program has been out-licensed to Virpax Pharmaceuticals, where it is also identified by the code VRP124.
- Brand names
- NobrXiolNaltos Nasal Powder
02
Targets
CACNA1G (T-type Calcium Channel Protein Subunit Alpha-1G)ABAT (4-aminobutyrate aminotransferase)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)
Beyond the preview
Go deeper on NB128.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NB128.